trial

Intranasal Insulin Treatment in Patients With Schizophrenia

NCTId NCT00575666
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 45 (actual)
Sponsored by University of Massachusetts, Worcester
Primary completion 2010-09
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
45 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2007-12
Primary completion
2010-09
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
—

Sponsors

University of Massachusetts, WorcesterLead Sponsor
National Alliance for Research on Schizophrenia and DepressionCollaborator
Eli Lilly and CompanyCollaborator

Investigators

1
Xiaoduo Fan, MD, MPH, MSPrincipal Investigator

Sites

1 total
Worcester, United States

Facts & assertions

4 sourced
Enrollment
45
Phase
PHASE4
Primary Completion Date
2010-09
Status
COMPLETED
relationships
The graph out of here
lead_sponsor
University of Massachusetts, Worcester
company
collaborator
National Alliance for Research on Schizophrenia and Depression
company
Eli Lilly and Company
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Xiaoduo Fan, MD, MPH, MS
person